BMY vs PTCT · P/E 17, rev $24.46B vs rev $633.1M
Bristol-Myers Squibb Company (BMY) versus PTC Therapeutics Inc (PTCT) — a side-by-side from cached financials, not a winner call.
Bristol-Myers Squibb Company (BMY) is a drug manufacturers - general company listed on US. It is led by Chris Boerner.
PTC Therapeutics Inc (PTCT) is a biotechnology company listed on NASDAQ.
Latest reported BMY revenue for 2026-06-30 was $24.46B. Net income was $5.99B. BMY currently screens at market cap $95.36B and trailing P/E 17.5.
Latest reported PTCT revenue for 2026-06-30 was $633.1M. Net income was $80.7M. PTCT currently screens at market cap $6.51B.
BMY currently screens at market cap $95.36B and trailing P/E 17.5. PTCT currently screens at market cap $6.51B.
Not investment advice. Open the BMY and PTCT stock pages for the full models.
Not investment advice.